UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008764
Receipt number R000010209
Scientific Title A phase II trial of pemetrexed/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Date of disclosure of the study information 2012/08/24
Last modified on 2014/08/24 09:04:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase II trial of pemetrexed/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.

Acronym

A phase II trial of pemetrexed/bevacizumab in elderly patients with advanced NSCLC.

Scientific Title

A phase II trial of pemetrexed/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.

Scientific Title:Acronym

A phase II trial of pemetrexed/bevacizumab in elderly patients with advanced NSCLC.

Region

Japan


Condition

Condition

elderly patients with stage IIIB/IV non-small cell lung cancer except for squamous cell carcinoma

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of pemetrexed/bevacizumab in elderly patients with advanced non-small cell lung cancer except for squamous cell carcinoma

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

response rate

Key secondary outcomes

disease control rate, progression free survival, overall survival, safety, QOL


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Pemetrexed(500mg/m2) and bevacizumab(15mg/kg) will be administered triweekly until disease progression.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

75 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) histologically confirmed non-small cell lung cancer except for squamous cell carcinoma
2) clinical stage IIIB/IV or relapsed case
3) chemotherapy naive
4) PS (ECOG) 0-1
5) with mesurable lesions
6) more than 75 years old
7) with sufficient bone marrow, liver and kidney function
8) with asymptomatic and/or well controled brain metastases
9) estimated survival is more than 3 months
10) with written informed consent

Key exclusion criteria

1) history of hemoptysis (more than 2.5mL)
2) with pulmonary cavitary lesions
3) with invasion to the aorta and/or pulmonary arteries
4) tumor outcrop in main bronchus
5) history of radical thoracic radiotherapy
6) patients treated by anti-coagulation therapy complicated with brain metastasis
7) with severe infection
8) with massive pleural effusion, ascites or pericardial effusion
9) overlapped with other malignancies
10) with severe peptic ulcer
11) history of perforation in digestive tract

Target sample size

36


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuhiko Nishioka

Organization

The University of Tokushima Graduate School, Institute of Health Biosciences

Division name

Department of Respiratory Medicine and Rheumatology

Zip code


Address

3-8-15, Kuramoto-cho, Tokushima

TEL

088-633-7127

Email

yasuhiko@tokushima-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masaki Hanibuchi

Organization

The University of Tokushima Graduate School, Institute of Health Biosciences

Division name

Department of Respiratory Medicine and Rheumatology

Zip code


Address

3-8-15, Kuramoto-cho, Tokushima

TEL

088-633-7127

Homepage URL


Email

mhoney@tokushima-u.ac.jp


Sponsor or person

Institute

Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School

Institute

Department

Personal name



Funding Source

Organization

Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

徳島大学病院(徳島県)、徳島県立中央病院(徳島県)、徳島市民病院(徳島県)、高松赤十字病院(香川県)、国立病院機構高知病院(高知県)、高知医療センター(高知県)、高知赤十字病院(高知県)、松山赤十字病院(愛媛県)、国立病院機構大阪医療センター(大阪府)、聖路加国際病院(東京都)


Other administrative information

Date of disclosure of the study information

2012 Year 08 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2012 Year 08 Month 14 Day

Date of IRB


Anticipated trial start date

2012 Year 10 Month 01 Day

Last follow-up date

2014 Year 08 Month 31 Day

Date of closure to data entry

2017 Year 08 Month 31 Day

Date trial data considered complete

2017 Year 08 Month 31 Day

Date analysis concluded

2017 Year 08 Month 31 Day


Other

Other related information



Management information

Registered date

2012 Year 08 Month 24 Day

Last modified on

2014 Year 08 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010209


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name